Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.
| Revenue (TTM) | $25.61B |
| Gross Profit (TTM) | $15.20B |
| EBITDA | $8.26B |
| Operating Margin | 21.10% |
| Return on Equity | 8.19% |
| Return on Assets | 4.06% |
| Revenue/Share (TTM) | $36.27 |
| Book Value | $76.23 |
| Price-to-Book | 2.97 |
| Price-to-Sales (TTM) | 6.32 |
| EV/Revenue | 7.03 |
| EV/EBITDA | 23.04 |
| Quarterly Earnings Growth (YoY) | 37.80% |
| Quarterly Revenue Growth (YoY) | 8.30% |
| Shares Outstanding | $702.99M |
| Float | $626.35M |
| % Insiders | 10.81% |
| % Institutions | 83.42% |
Volatility is currently contracting
WASHINGTON, Nov. 2, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Julie Sawyer Montgomery, will be presenting at the UBS Global Healthcare Conference in Palm Beach, Florida on Monday, November 9, 2026 at 11:45 a.m. ET and Jefferies Global Healthcare Conference in London, UK on November 17, 2026 at 10:00 a.m.
Danaher (DHR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Investors interested in Medical Services stocks are likely familiar with Labcorp Holdings (LH) and Danaher (DHR). But which of these two stocks is more attractive to value investors?
Danaher Corporation is rated hold, as the stock trades at a small premium and offers an 8.85% expected return, below my threshold. Q3 earnings showed solid performance: revenue up 8.3% YoY to $6.55B, adjusted EPS of $2.11, and strong segment growth, especially in Diagnostics. Key headwinds include respiratory revenue volatility and pricing pressure from China's volume-based procurement, despite some recent positive trends.
It beat analyst estimates for both revenue and profitability. Its full-year earnings guidance also topped the pundit consensus.
Danaher Corporation ( DHR ) Q3 2026 Earnings Call October 21, 2026 8:00 AM EDT Company Participants Rachel Vatnsdal Olson - Vice President of Investor Relations Julie Montgomery - President, CEO & Director Matthew Gugino - Executive VP & CFO Conference Call Participants Doug Schenkel Vijay Kumar - Evercore ISI Institutional Equities, Research Division Tycho Peterson - Jefferies LLC, Research Division Jack Meehan - Operon Research, LLC Scott Davis - Melius Research LLC Casey Woodring - JPMorgan Chase & Co, Research Division Elizabeth Koslosky - Goldman Sachs Group, Inc., Research Division Presentation Operator My name is Chelsea, and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to Danaher Corporation's Third Quarter 2026 Earnings Results Conference Call.
Danaher raised full-year earnings per share guidance to $8.57 to $8.62. Biotechnology orders grew mid-teens during the third quarter.
Danaher Corporation delivered mixed Q3 results, with revenue up 8.3% y/y but growth driven mainly by acquisitions and tariff refunds. Adjusted operating margin reached 29%, exceeding guidance, yet organic growth and profitability improvements remain modest and partly non-recurring. Management's Q4 guidance implies lower-than-expected EPS, and the new CEO signals a need for stronger growth and operational execution.
Danaher's third-quarter earnings beat estimates by 9.9%, driven by stronger Biotechnology profitability, while it raised its 2026 adjusted earnings outlook.
Danaher NYSE: DHR reported third-quarter 2026 results that exceeded its expectations, citing improved market conditions, commercial execution and operational performance across its Biotechnology, Life Sciences and Diagnostics businesses.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on DHR and any ticker you trade — then tracks every position and per-strategy win rate.
